Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04713098 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotableResults posted: Sep 24, 2026Eligibility criteria expanded, about 16 words · Secondary endpoints: details revised at 6 of 7 entries · Study description expanded, about 23 wordsShow 3 more changesShow less
Eligibility criteria expanded, about 16 words
Secondary endpoints: details revised at 6 of 7 entries
Study description expanded, about 23 words
MinorSecondary endpoints revised (7)Primary endpoints revised (2)v18Show 1 more changeShow less
NotablePrimary completion date: Feb 1, 2025 to Sep 22, 2025v17
Minor2 versionsRe-verified since Dec 17, 2025, no change to tracked fieldsv15-v16
MinorTrial status: Active, Not Recruiting to CompletedStudy completion date changed from estimate of Jan 22, 2026 to Sep 22, 2025v14Show 1 more changeShow less
Study completion date changed from estimate of Jan 22, 2026 to Sep 22, 2025
Show 12 earlier versionsHide 12 earlier versions
MinorPrimary completion date: Oct 15, 2024 to Feb 1, 2025Completion date: Oct 7, 2025 to Jan 22, 2026v13Show 1 more changeShow less
Completion date: Oct 7, 2025 to Jan 22, 2026
MinorTrial status: Enrolling by Invitation to Active, Not Recruitingv12
Minor2 versionsRe-verified since Mar 24, 2025, no change to tracked fieldsv10-v11
MinorPrimary completion date: Jul 15, 2024 to Oct 15, 2024Completion date: Jun 15, 2025 to Oct 7, 2025v9Show 1 more changeShow less
Completion date: Jun 15, 2025 to Oct 7, 2025
MinorRe-verified, no change to tracked fieldsv8
NotablePrimary completion date: Dec 31, 2023 to Jul 15, 2024Completion date: Dec 15, 2024 to Jun 15, 2025v7Show 1 more changeShow less
Completion date: Dec 15, 2024 to Jun 15, 2025
NotablePrimary completion date: Jan 26, 2023 to Dec 31, 2023Completion date: Jan 26, 2024 to Dec 15, 2024v6Show 1 more changeShow less
Completion date: Jan 26, 2024 to Dec 15, 2024
MinorStudy sites: 5 to 6v5
MinorRe-verified, no change to tracked fieldsv4
NotableTrial status: Not Yet Recruiting to Enrolling by InvitationPrimary completion date: Jan 28, 2023 to Jan 26, 2023 · Completion date: Jan 28, 2024 to Jan 26, 2024 · Start date changed from estimate of Jan 28, 2021 to Jan 26, 2021 · 1 morev3Show 4 more changesShow less
Primary completion date: Jan 28, 2023 to Jan 26, 2023
Completion date: Jan 28, 2024 to Jan 26, 2024
Start date changed from estimate of Jan 28, 2021 to Jan 26, 2021
Site contacts updated at 5 of 5 sites
MinorRe-verified, no change to tracked fieldsv2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Postoperative pain is usually treated with opioids that have undesirable and sometimes dangerous side effects (e.g., vomiting and respiratory depression)-and yet over 80% of patients still experience inadequate pain relief. A novel, non-pharmacologic analgesic technique-percutaneous peripheral nerve stimulation (PNS)- holds extraordinary potential to greatly reduce or obviate opioid requirements and concurrently improve analgesia following painful surgery. This technique involves inserting an insulated electric lead adjacent to a target nerve through a needle prior to surgery using ultrasound guidance. Following surgery, a tiny electric current is delivered to the nerve resulting in potent pain control without any cognitive or adverse systemic side effects whatsoever. The electrical pulse generator (stimulator) is so small it is simply affixed to the patient's skin. The leads are already cleared by the US Food and Drug Administration to treat acute (postoperative) pain for up to 60 days; and, since percutaneous PNS may be provided on an outpatient basis, the technique holds the promise of providing potent analgesia outlasting the pain of surgery-in other words, the possibility of a painless, opioid-free recovery following surgery.
The current project is a multicenter, randomized, quadruple-masked, placebo/sham-controlled, parallel-arm pragmatic clinical trial to determine the effects of percutaneous PNS on postoperative analgesia and opioid requirements, as well as physical and emotional functioning, the development of chronic pain, and ongoing quality of life.